Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer--another step forward.
作者信息
Pater Joseph L, Parulekar Wendy R
出版信息
J Natl Cancer Inst. 2003 Dec 17;95(24):1811-2. doi: 10.1093/jnci/djg133.
PMID:14679143
Abstract
摘要
相似文献
1
Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer--another step forward.
J Natl Cancer Inst. 2003 Dec 17;95(24):1811-2. doi: 10.1093/jnci/djg133.
2
Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Oncology (Williston Park). 2009 Jan;23(1):27-33.
3
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46. doi: 10.1093/jnci/djg119.
4
Reversible ovarian ablation or chemotherapy: are we ready for quality of life to guide adjuvant treatment decisions in breast cancer?
J Clin Oncol. 2003 Dec 15;21(24):4474-5. doi: 10.1200/JCO.2003.07.966. Epub 2003 Nov 10.
5
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
J Clin Oncol. 2007 Jan 20;25(3):263-70. doi: 10.1200/JCO.2005.04.5393. Epub 2006 Dec 11.
6
Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer.
Eur J Cancer. 2004 Nov;40(16):2403-10. doi: 10.1016/j.ejca.2004.07.013.
7
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
Eur J Cancer. 2006 Aug;42(12):1780-8. doi: 10.1016/j.ejca.2006.04.006. Epub 2006 Jun 12.
8
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Breast Cancer Res Treat. 2009 Oct;117(3):561-7. doi: 10.1007/s10549-009-0313-5. Epub 2009 Jan 20.
9
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
Osteoporos Int. 2003 Dec;14(12):1001-6. doi: 10.1007/s00198-003-1508-y. Epub 2003 Oct 3.
10
Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group.
J Clin Oncol. 2003 Dec 15;21(24):4510-6. doi: 10.1200/JCO.2003.11.064. Epub 2003 Nov 10.
引用本文的文献
1
Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant).
South Asian J Cancer. 2018 Apr-Jun;7(2):151-155. doi: 10.4103/sajc.sajc_125_18.
2
Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer.
Surg Today. 2011 Jan;41(1):48-53. doi: 10.1007/s00595-009-4226-z. Epub 2010 Dec 30.
3
Recovery of menstruation after long-term chemotherapy and endocrine therapy in pre-menopausal patients with breast cancer.
J Cancer Res Clin Oncol. 2011 Apr;137(4):615-20. doi: 10.1007/s00432-010-0894-8. Epub 2010 Jun 9.
Zotero 插件